Risk management planning: Time to deliver

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 12, 2006, Pages 850-851

  Waller, Patrick ^a  

^a Department of Pharmacoepidemiology ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CLOZAPINE; ISOTRETINOIN; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR;

AGRANULOCYTOSIS; DECISION MAKING; DRUG CONTRAINDICATION; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; INTERNATIONAL COOPERATION; LONG TERM CARE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SUICIDAL IDEATION;

EID: 33845599928     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1326     Document Type: Note

References (14)

1. Mitchell AA, Van Bennekom CM, Louik CA. Pregnancy-Prevention Program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106.
2. Alvir J, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis-Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-167.
3. Hirst C, Cook S, Dai W, Perez-Gutthann S, Andrews E. A call for international harmonisation in therapeutic risk management. Pharmacoepidemiol Drug Saf 2006; 15: 839-849.
4. Ferner RE, Aronson JK. Communicating about drug safety. Br Med J 2006; 333: 143-145.
5. Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 1383-1384.
6. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004; 364: 1995-1996.
7. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. Br Med J 2005; 330: 373-374.
8. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12: 17-29.
9. ICH Harmonised Tripartite Guideline E2E. Pharmacovigilance Planning. http://www.ich.org/Mediaserver.jser?ID=1195MODE=GLB
10. EMEA guideline on risk management systems for medicinal products for human use. http://www.emea.eu.int/pdfs/human/euleg/9626805en.pdf
11. Pre-marketing Risk Assessment. FDA Guidance for Industry, March 2005. http://www.fda.gov/cder/guidance/6357fnl.htm.
12. Development and Use of Risk Minimization Action Plans. FDA Guidance for Industry, March 2005. http://www.fda.gov/cder/guidance/6358fnl.htm
13. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. FDA Guidance for Industry, March 2005. http://www.fda.gov/cder/guidance/ 6359OCC.htm
14. Wood AJJ. A proposal for radical changes in the drug-approval process. N Engl J Med 2005; 355: 618-623.